NWRN — Newron Pharmaceuticals SpA Share News
0.000.00%
Last trade - 00:00- CH₣174.16m
- CH₣182.76m
- €19.13m
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study
Brief: Newron Announces Agreement With The European Investment Bank (Eib) To Extend The Near-Term Tranche Repayment Dates Of Its 2018 Finance Contract
Brief: Newron Secures Up To 38 Million Euros To Advance Phase III Evenamide Program
Brief: Newron Pharmaceuticals SpA Says Topline Results For ENIGMA-TRS 2 Phase III Global Study Are Expected In Q4 2026
Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal
Brief: Newron Notes the Publication of New Preclinical Research
Brief: Newron Announces Approval For Pivotal Phase Iii Enigma-Trs Program With Evenamide As Add-On Therapy In Patients With Treatment-Resistant Schizophrenia (Trs)
Brief: Newron And EA Pharma Announce License Agreement For Evenamide In Japan And Other Asian Territories
Brief: Newron Announces Positive Top-Line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide In Schizophrenia Patients
Brief: Newron Announces Agreement With The EIB To Extend The Near-Term Tranche Repayment Dates Of Its 2018 Financing Agreement
Brief: Newron Pharmaceuticals Says Co Enters Into Agreement For The Subscription Of Up To 2.05 Mln Newly Issued Shares; Proceeds Of Up To EUR 15.0 Mln
Brief: Newron Reports 1 Year Results Of Study 014/15 In Treatment-Resistant Schizophrenia
Brief: Newron Completes Enrollment Of Schizophrenia Patients In Potentially Pivotal Study 008A With Evenamide
Brief: Newron Pharmaceuticals SpA Says Roberto Galli Has Been Promoted To Chief Financial Officer As Of July 1, 2023
Brief: Newron Presents Six-Month Interim Data From The First 100 Patients Randomized In Study 014/015 At The 31St European Congress Of Psychiatry
Brief: Newron Reports Compelling Topline Results From All Patients In Study 014